相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Immunology
Vladislav Izda et al.
Summary: The COVID-19 pandemic has become a major global public health crisis, prompting urgent efforts in the scientific community to search for therapeutic and preventative solutions, including the development of pharmacological therapies and vaccines. This article aims to review the latest data on pharmacological therapies undergoing clinical trials and vaccine candidates in development to combat COVID-19.
CLINICAL IMMUNOLOGY
(2021)
Editorial Material
Medicine, General & Internal
Adam S. Lauring et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Ann Gibbons
Article
Cell Biology
Shuai Lu et al.
Summary: The study reveals that predicted epitopes on SARS-CoV-2 effectively induce antibody production, with some being immunodominant. There are differences in immunodominant epitopes between individuals with domestic and imported SARS-CoV-2, possibly due to mutations on the proteins. Several epitopes on the S protein elicit neutralizing antibodies against different variants of SARS-CoV-2, showing potential for vaccine design against coronaviruses.
Article
Microbiology
Allison J. Greaney et al.
Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.
CELL HOST & MICROBE
(2021)
Editorial Material
Medicine, General & Internal
John R. Mascola et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Medicine, General & Internal
Wenjuan Zhang et al.
Summary: The research focused on sequencing and phylogenetic analyses of SARS-CoV-2 isolates from symptomatic patients at Cedar-Sinai Medical Center in November-December 2020, providing insights into a surge in cases and hospitalizations during that period.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Microbiology
Alejandro Flores-Alanis et al.
Summary: The study analyzed 2213 complete genomes of SARS-CoV-2 from six geographical regions worldwide, finding low genetic diversity but an increase over time with hotspot mutations. The research identified four mutations associated with disease severity.
Article
Multidisciplinary Sciences
Alex Graudenzi et al.
Summary: This study conducted a large-scale analysis of intra-host genomic diversity of SARS-CoV-2, revealing interactions between host-related mutational processes and transmission dynamics, as well as identifying mutational signatures related to nucleotide substitutions. The study also demonstrated the impact of purifying selection on these mutational processes, while some mutations transition towards clonality, increasing overall genomic diversity. Additionally, phylogenomic analysis supported the hypothesis of transmission of minor variants, paving the way for integrated analysis of intra-host genomic diversity and clinical outcomes of SARS-CoV-2 infections.
Article
Biochemistry & Molecular Biology
Xianding Deng et al.
Summary: A new SARS-CoV-2 variant named B.1.427/B.1.429 was identified in California, with increased transmissibility and carrying three mutations in spike protein, including L452R substitution. The variant emerged in May 2020 and became predominant in sequenced cases from September 2020 to January 2021. In vivo viral shedding was increased and antibody neutralization decreased, calling for further investigation.
Article
Microbiology
Chihiro Motozono et al.
Summary: Research has shown that certain mutations in SARS-CoV-2 variants can escape HLA-restricted cellular immunity, increase affinity for host cells, promote viral replication, and potentially affect the evolution of viral phenotypes.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Matthew McCallum et al.
Summary: The novel CAL.20C (B.1.427/B.1.429) variant carries spike protein mutations, resulting in reduced neutralizing titers in vaccinated individuals and convalescent individuals. The L452R mutation reduces neutralizing activity in RBD-specific monoclonal antibodies, while the S13I and W152C mutations lead to the total loss of neutralization in NTD-specific antibodies due to antigenic supersite remodeling.
Correction
Multidisciplinary Sciences
Zhiqiang Ku et al.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Ashlesha Deshpande et al.
Summary: This study investigated the impact of RBD mutations in SARS-CoV-2 on ACE2 and NAb binding, revealing that mutations such as K417T, E484K, and N501Y disrupted the binding of 65% of evaluated NAbs, indicating concern for the P.1 Japan/Brazil strain. Additionally, the L452R mutation enhanced ACE2 binding affinity while disrupting C1 and C2 NAb classes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Article
Biochemistry & Molecular Biology
Jiahui Chen et al.
JOURNAL OF MOLECULAR BIOLOGY
(2020)
Review
Immunology
Omna Sharma et al.
FRONTIERS IN IMMUNOLOGY
(2020)
Correction
Biochemistry & Molecular Biology
Alexandra C. Walls et al.
